Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combinations in Refractory NKTCL
NCT05058755Completed
- Sponsor
- Xinhua Hospital
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of tislelizumab in natural killer/T-cell lymphoma (NKTL) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT05058755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058755.